Format

Send to

Choose Destination
Eur J Haematol. 2020 Feb 12. doi: 10.1111/ejh.13395. [Epub ahead of print]

Long-term follow-up of Cladribine, high-dose Cytarabine and Idarubicin as salvage treatment for Relapsed acute myeloid Leukemia and Literature Review.

Author information

1
Medizinische Klinik III, Hämatologie/Onkologie/Rheumatologie, Universitätsklinikum Bonn, Bonn, Germany.
2
Abteilung für Integrierte Onkologie, Universitätsklinikum Bonn, Bonn, Germany.
3
Klinik für Innere Medizin II, Abteilung für Hämatologie und Onkologie, Universitätsklinikum Jena, Jena, Germany.
4
Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie, Hans-Knöll Institut, Center for Sepsis Control and Care (CSCC), Universitätsklinikum Jena, Jena, Germany.

Abstract

PURPOSE:

Outcome for relapsed acute myeloid leukemia (AML) is poor. Cladribine has activity in AML and an enhancing effect on other cytostatic drugs thus may help overcome resistance. Here, we present the final analysis of our phase II trial evaluating safety and efficacy of cladribine, cytarabine and idarubicin (CAI) in relapsed AML.

METHODS:

Patients with relapsed AML after at least six months remission received two courses of CAI. After nine patients, prolonged neutropenia prompted protocol change (omission of idarubicin in 2nd course and dose-reduction of cytarabine). Primary endpoints were remission rate and safety.

RESULTS:

Twenty patients received treatment, fourteen one and six two courses CAI/CA. After first course, complete remission (CR/CRi) was achieved in 60%. Most frequent toxicity was infection. Median OS was 8.8 months in all patients and 21.1 months in those with CR. Nine patients (48%) proceeded to allogeneic stem cell transplantation (allo-SCT), four of those are still alive and in CR, accounting for a 5-year survival rate of 55% of transplanted patients.

CONCLUSION:

CAI in relapsed AML is feasible and induces good response rates. As expected, infections are the most important complication. However, combined with allo-SCT, long-term survival can be achieved in a substantial number of patients.

KEYWORDS:

Relapsed AML; allogeneic stem cell transplantation; cladribine; complete remission; infection; neutropenia; treatment related mortality

PMID:
32049382
DOI:
10.1111/ejh.13395

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center